Alfonso Maresca1, Claudiu T Supuran. 1. Università degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, I-50019 Sesto Fiorentino, Firenze, Italy.
Abstract
BACKGROUND: There are five types of muscarinic acetylcholine receptors (mAChRs), M(1) - M(5), which regulate several central and peripheral functions. Transgenic mice deficient in these receptors have been generated. OBJECTIVE: To understand some processes in which these receptors are involved, mainly targeting obesity, which seems to be mediated by M(3) in the hypothalamus. METHODS: The absence of M(3) has beneficial effects, which protect mice against some forms of obesity and ameliorate glucose and energy homeostasis. These findings suggest some relevance of muscarinic M(3) antagonists to the treatment of obesity, and also studies with new classes of M(3)-receptor selective antagonists, to identify active/selective molecules, able to reach the CNS, which might have fewer side-effects compared with available muscarinic drugs. RESULTS/ CONCLUSION: M(3) antagonists might have application to the design of antiobesity agents. However, this research is in its preliminary phases, and the lack of specific antagonists or agonists for M(3) receptors in CNS, make it impossible to validate this antiobesity target at present.
BACKGROUND: There are five types of muscarinic acetylcholine receptors (mAChRs), M(1) - M(5), which regulate several central and peripheral functions. Transgenic mice deficient in these receptors have been generated. OBJECTIVE: To understand some processes in which these receptors are involved, mainly targeting obesity, which seems to be mediated by M(3) in the hypothalamus. METHODS: The absence of M(3) has beneficial effects, which protect mice against some forms of obesity and ameliorate glucose and energy homeostasis. These findings suggest some relevance of muscarinic M(3) antagonists to the treatment of obesity, and also studies with new classes of M(3)-receptor selective antagonists, to identify active/selective molecules, able to reach the CNS, which might have fewer side-effects compared with available muscarinic drugs. RESULTS/ CONCLUSION: M(3) antagonists might have application to the design of antiobesity agents. However, this research is in its preliminary phases, and the lack of specific antagonists or agonists for M(3) receptors in CNS, make it impossible to validate this antiobesity target at present.
Authors: Douglas J Sheffler; Richard Williams; Thomas M Bridges; Zixiu Xiang; Alexander S Kane; Nellie E Byun; Satyawan Jadhav; Mathew M Mock; Fang Zheng; L Michelle Lewis; Carrie K Jones; Colleen M Niswender; Charles D Weaver; Craig W Lindsley; P Jeffrey Conn Journal: Mol Pharmacol Date: 2009-04-30 Impact factor: 4.436
Authors: Chuanhui Dong; Ashley Beecham; Susan Slifer; Liyong Wang; Mark S McClendon; Susan H Blanton; Tatjana Rundek; Ralph L Sacco Journal: Hum Genet Date: 2010-11-21 Impact factor: 4.132